BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6097684)

  • 1. The hCG assay in the treatment of trophoblastic disease.
    Pattillo RA; Hussa RO
    J Reprod Med; 1984 Nov; 29(11):802-12. PubMed ID: 6097684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results.
    Cole LA; Khanlian SA; Giddings A; Butler SA; Muller CY; Hammond C; Kohorn E
    Gynecol Oncol; 2006 Aug; 102(2):165-72. PubMed ID: 16631243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of macrophage colony-stimulating factor in trophoblastic disease.
    Kohorn EI; Kacinski BM; Stanley ER
    Gynecol Oncol; 2001 Mar; 80(3):383-6. PubMed ID: 11263936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum granulocyte macrophage colony stimulating factor (GM-CSF) in gestational trophoblastic diseases.
    Shaarawy M; el-Shobokshy AS; el-Noury AI
    Cytokine; 1995 Feb; 7(2):171-5. PubMed ID: 7540057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
    Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
    Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of hCG in trophoblastic disease. The USA hCG reference service experience.
    Cole LA; Butler S
    J Reprod Med; 2002 Jun; 47(6):433-44. PubMed ID: 12092011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent low-level "real" human chorionic gonadotropin: a clinical challenge and a therapeutic dilemma.
    Kohorn EI
    Gynecol Oncol; 2002 May; 85(2):315-20. PubMed ID: 11972394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of remission in trophoblastic disease as seen from serum hCG level (author's transl)].
    Hirashima N
    Nihon Sanka Fujinka Gakkai Zasshi; 1980 May; 32(5):592-600. PubMed ID: 6263999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free beta-subunit, a reliable marker of placental site trophoblastic tumors.
    Cole LA; Khanlian SA; Muller CY; Giddings A; Kohorn E; Berkowitz R
    Gynecol Oncol; 2006 Aug; 102(2):160-4. PubMed ID: 16631918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia.
    Cole LA; Butler SA; Khanlian SA; Giddings A; Muller CY; Seckl MJ; Kohorn EI
    Gynecol Oncol; 2006 Aug; 102(2):151-9. PubMed ID: 16631241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of CA-125 in trophoblastic disease.
    Kohorn EI
    Gynecol Oncol; 2000 Jul; 78(1):39-42. PubMed ID: 10873407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring therapy in trophoblastic diseases by radioimmunoassay of pregnancy-specific beta 1-glycoprotein and the beta subunit of human chorionic gonadotropin.
    Than GN; Csaba IF; Bohn H; Szabó DG; Szalmásy M; Menczer G
    Oncodev Biol Med; 1982; 3(4):315-23. PubMed ID: 6291007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
    Shaarawy M; Darwish NA; Abdel-Aziz O
    J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease.
    van Trommel NE; Massuger LF; Schijf CP; ten Kate-Booij MJ; Sweep FC; Thomas CM
    J Clin Oncol; 2006 Jan; 24(1):52-8. PubMed ID: 16382113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of pregnancies occurring before completion of human chorionic gonadotropin follow-up in patients with persistent gestational trophoblastic tumor.
    Tuncer ZS; Bernstein MR; Goldstein DP; Berkowitz RS
    Gynecol Oncol; 1999 Jun; 73(3):345-7. PubMed ID: 10366457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
    Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
    Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of human chorionic gonadotropin and alpha-subunit measurements.
    Hussa RO
    Obstet Gynecol; 1982 Jul; 60(1):1-12. PubMed ID: 6283446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of persistent trophoblastic tumour by serum human chorionic gonadotrophin monitoring after molar pregnancy.
    Ngan HY; Wong LC
    Chin Med J (Engl); 1999 Mar; 112(3):260-3. PubMed ID: 11593563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
    Wolfberg AJ; Berkowitz RS; Goldstein DP; Feltmate C; Lieberman E
    Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management and outcome of healthy women with a persistently elevated beta-hCG.
    Palmieri C; Dhillon T; Fisher RA; Young AM; Short D; Mitchell H; Aghajanian C; Savage PM; Newlands ES; Hancock BW; Seckl MJ
    Gynecol Oncol; 2007 Jul; 106(1):35-43. PubMed ID: 17482245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.